Evidence map›Paper›PMID 35712268›Full record

SynthesisFrontiers in public health2022

Determinants of COVID-19 Vaccine Engagement in Algeria: A Population-Based Study With Systematic Review of Studies From Arab Countries of the MENA Region.

Salah Eddine Oussama Kacimi, Selma Nihel Klouche-Djedid, Omar Riffi, Hadj Ahmed Belaouni, Farah Yasmin, Mohammad Yasir Essar, Fatma Asma Taouza, Yasmine Belakhdar, Saliha Chiboub Fellah, Amira Yasmine Benmelouka and 7 more

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 11 institutions in 6 countries.

Salah Eddine Oussama KacimiDepartment of Medicine, Faculty of Medicine, University of Tlemcen, Tlemcen, Algeria.
Selma Nihel Klouche-DjedidDepartment of Medicine, Faculty of Medicine, University of Tlemcen, Tlemcen, Algeria.
Omar RiffiDepartment of Medicine, Faculty of Medicine, University of Tlemcen, Tlemcen, Algeria.
Hadj Ahmed BelaouniLaboratoire de Biologie des Systèmes Microbiens (LBSM), Ecole Normale Supérieure de Kouba, Algiers, Algeria.
Farah YasminDow University of Health Sciences, Karachi, Pakistan.
Mohammad Yasir EssarKabul University of Medical Sciences, Kabul, Afghanistan.
Fatma Asma TaouzaFaculty of Medicine, University of Oran, Oran, Algeria.
Yasmine BelakhdarFaculty of Medicine, University of Annaba, Annaba, Algeria.
Saliha Chiboub FellahDepartment of Medicine, Faculty of Medicine, University of Tlemcen, Tlemcen, Algeria.
Amira Yasmine BenmeloukaFaculty of Medicine, University of Algiers, Algiers, Algeria.
Shoaib AhmedPunjab Medical College, Faisalabad, Pakistan.
Mohammad AloulouFaculty of Medicine, University of Aleppo, Aleppo, Syria.
Abdellah BendelhoumDepartment of Medicine, Faculty of Medicine, University of Tlemcen, Tlemcen, Algeria.
Hafida MerzoukLaboratory of Physiology, Physiopathology and Biochemistry of Nutrition, Department of Biology, Faculty of Natural and Life Sciences, Earth and Universe, University of Tlemcen, Tlemcen, Algeria.
Sherief GhozyNeurovascular Research Lab, Radiology Department, Mayo Clinic, Rochester, MN, United States.
Jaffer ShahMedical Research Center, Kateb University, Kabul, Afghanistan.
Mohamed Amine HairecheResearch Department, Scientia Vallis, Paris, France.
University of Abou Bekr Belkaïd · DZBadji Mokhtar University · DZDow University of Health Sciences · PKÉcole Normale Supérieure de Kouba · DZKabul Medical University · AFKabul University · AFPunjab Medical College · PKUniversité Oran 1 Ahmed Ben Bella · DZUniversity of Aleppo · SYUniversity of Algiers 3 · DZUniversity of Oxford · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The Algerian COVID-19 vaccination campaign, which started at the end of January 2021, is marked by a slowly ascending curve despite the deployed resources. To tackle the issue, we assessed the levels and explored determinants of engagement toward the COVID-19 vaccine among the Algerian population. Methods: A nationwide, online-based cross-sectional study was conducted between March 27 and April 30, 2021. A two-stage stratified snowball sampling method was used to include an equivalent number of participants from the four cardinal regions of the country. A vaccine engagement scale was developed, defining vaccine engagement as a multidimensional parameter (5 items) that combined self-stated acceptance and willingness with perceived safety and efficacy of the vaccine. An Engagement score was calculated and the median was used to define engagement vs. non-engagement. Sociodemographic and clinical data, perceptions about COVID-19, and levels of adherence to preventive measures were analyzed as predictors for non-engagement. Results: We included 1,019 participants, 54% were female and 64% were aged 18-29 years. Overall, there were low rates of self-declared acceptance (26%) and willingness (21%) to take the vaccine, as well as low levels of agreement regarding vaccine safety (21%) and efficacy (30%). Thus, the vaccine engagement rate was estimated at 33.5%, and ranged between 29.6-38.5% depending on the region ( Conclusions: The very low rates of vaccine engagement among the Algerian population probably explain the slow ascension of the vaccination curve in the country. Vaccine awareness campaigns should be implemented to address the multiple misconceptions and enhance the levels of knowledge and perception both about the disease and the vaccine, by prioritizing target populations and engaging both healthcare workers and the general population.

Indexed as

COVID-19COVID-19 VaccinesAlgeriaArabsCross-Sectional StudiesFemaleHumansMaleSurveys and QuestionnairesCOVID-19 VaccinesacceptanceAlgeriaCOVID-19hesitancyimmunizationMiddle-East and North African (MENA)SARS-CoV-2vaccine

Identifiers

PMID35712268
PMCPMC9196869
OpenAlexW4281744287

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.